Cartesian Therapeutics (RNAC) Non-Current Debt (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Non-Current Debt for 8 consecutive years, with $13.8 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Non-Current Debt fell 39.09% year-over-year to $13.8 million; the TTM figure through Jun 2023 stood at $13.8 million (down 39.09% YoY), while the FY2022 annual figure was $17.8 million, down 9.59% from the prior year.
• Non-Current Debt declined to $13.8 million in Q2 2023 per RNAC's latest filing, from $16.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $25.0 million in Q1 2022 and bottomed at $6.4 million in Q2 2020.
• Historically, Non-Current Debt has averaged $20.0 million across 4 years, with a median of $21.3 million in 2021.
• Annual changes were most pronounced in 2021 — Non-Current Debt surged 255.57% — and 2023, when it plunged 39.09%.
• Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then retreated by 20.65% to $19.7 million in 2021, then declined by 9.59% to $17.8 million in 2022, then decreased by 22.48% to $13.8 million in 2023.
• Business Quant data shows RNAC's Non-Current Debt at $13.8 million in Q2 2023, $16.2 million in Q1 2023, and $17.8 million in Q4 2022.